Company intelligence / Profile preview

TG Therapeutics, Inc.

Morrisville, North Carolina, United States of Americagsaelibrary.gsa.gov ↗

Ownership: Public · TGTX
Employees: ~387
Development stage: Commercial

Overview

TG Therapeutics has received FDA approval for BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. Recent data presentations at the American Academy of Neurology 2025 annual meeting highlighted BRIUMVI's efficacy. The ENHANCE trial demonstrated consistent safety and tolerability in over 80 patients who received maintenance BRIUMVI dose in 30 minutes.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Monoclonal antibodies (glycoengineered monoclonal antibody)CAR T-cell therapyBTK inhibitors
Industry: Biotech

Drug pipeline

5 assets

ublituximab

Approved

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $8.5B
Total revenue: $240.3M
Enterprise value: $8.7B

Beyond the preview

Go deeper on TG Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG Therapeutics, Inc..

Explore the full profile